Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in J Nucl Med

Retrieve available abstracts of 77 articles:
HTML format
Text format



Single Articles


    April 2017
  1. YOUNG JD, Abbate V, Imberti C, Meszaros LK, et al
    68Ga-THP-PSMA: a PET imaging agent for prostate cancer offering rapid, room temperature, one-step kit-based radiolabeling.
    J Nucl Med. 2017 Apr 13. pii: jnumed.117.191882. doi: 10.2967/jnumed.117.191882.
    PubMed     Text format     Abstract available


  2. FENDLER WP, Calais J, Allen-Auerbach M, Bluemel C, et al
    68Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study.
    J Nucl Med. 2017 Apr 13. pii: jnumed.117.190827. doi: 10.2967/jnumed.117.190827.
    PubMed     Text format     Abstract available


  3. KESCH C, Kratochwil C, Mier W, Kopka K, et al
    Gallium-68 or Fluorine-18 for prostate cancer imaging?
    J Nucl Med. 2017 Apr 13. pii: jnumed.117.190157. doi: 10.2967/jnumed.117.190157.
    PubMed     Text format     Abstract available


  4. MILLER MP, Kostakoglu L, Pryma D, Yu JQ, et al
    Reader training for the re-staging of biochemically recurrent prostate cancer using fluciclovine (18F) PET/CT.
    J Nucl Med. 2017 Apr 6. pii: jnumed.116.188375. doi: 10.2967/jnumed.116.188375.
    PubMed     Text format     Abstract available


    March 2017
  5. GOFFIN KE, Joniau S, Tenke P, Slawin K, et al
    Phase 2 study of 99mTc-trofolastat SPECT/CT to identify and localize prostate cancer in intermediate- and high-risk patients undergoing radical prostatectomy and extended pelvic lymph node dissection.
    J Nucl Med. 2017 Mar 16. pii: jnumed.116.187807. doi: 10.2967/jnumed.116.187807.
    PubMed     Text format     Abstract available


  6. PIERT M, Shao X, Raffel DM, Davenport MS, et al
    Preclinical evaluation of 11C-sarcosine as a substrate of proton-coupled amino acid transporters and first human application in prostate cancer.
    J Nucl Med. 2017 Mar 16. pii: jnumed.116.173179. doi: 10.2967/jnumed.116.173179.
    PubMed     Text format     Abstract available


    February 2017
  7. EINSPIELER I, Rauscher I, Duwel C, Kronke M, et al
    Detection efficacy of hybrid 68Ga-PSMA ligand PET/CT in prostate cancer patients with biochemical recurrence after primary radiation therapy defined by Phoenix criteria.
    J Nucl Med. 2017 Feb 16. pii: jnumed.116.184457. doi: 10.2967/jnumed.116.184457.
    PubMed     Text format     Abstract available


    January 2017
  8. AFSHAR-OROMIEH A, Sattler LP, Mier W, Hadaschik B, et al
    The clinical impact of additional late PET/CT imaging with 68Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer.
    J Nucl Med. 2017 Jan 6. pii: jnumed.116.183483. doi: 10.2967/jnumed.116.183483.
    PubMed     Text format     Abstract available


    December 2016
  9. DIETLEIN F, Kobe C, Neubauer S, Schmidt M, et al
    PSA-stratified performance of 18F- and 68Ga-labeled tracers in PSMA-PET imaging of patients with biochemical recurrence of prostate cancer.
    J Nucl Med. 2016 Dec 1. pii: jnumed.116.185538.
    PubMed     Text format     Abstract available


    October 2016
  10. CARDINALE J, Schafer M, Benesova M, Bauder-Wust U, et al
    Preclinical Evaluation of [18F]PSMA-1007: A New PSMA-Ligand for Prostate Cancer Imaging.
    J Nucl Med. 2016 Oct 27. pii: jnumed.116.181768.
    PubMed     Text format     Abstract available


  11. RAHBAR K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, et al
    German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients.
    J Nucl Med. 2016 Oct 20. pii: jnumed.116.183194.
    PubMed     Text format     Abstract available


  12. KULKARNI HR, Singh A, Schuchardt C, Niepsch K, et al
    PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  13. ROWE SP, Drzezga A, Neumaier B, Dietlein M, et al
    Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  14. AFSHAR-OROMIEH A, Babich JW, Kratochwil C, Giesel FL, et al
    The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  15. PANDIT-TASKAR N, Veach DR, Fox JJ, Scher HI, et al
    Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  16. BALLAS LK, de Castro Abreu AL, Quinn DI
    What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  17. MANSI R, Minamimoto R, Macke H, Iagaru AH, et al
    Bombesin-Targeted PET of Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  18. SCHUSTER DM, Nanni C, Fanti S
    Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  19. BEHESHTI M, Rezaee A, Geinitz H, Loidl W, et al
    Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET/CT.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  20. CECI F, Castellucci P, Mapelli P, Incerti E, et al
    Evaluation of Prostate Cancer with 11C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  21. MAPELLI P, Incerti E, Ceci F, Castellucci P, et al
    11C- or 18F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  22. WEBER WA, Morris MJ
    Molecular Imaging and Targeted Radionuclide Therapy of Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format    


  23. NITSCH S, Hakenberg OW, Heuschkel M, Drager D, et al
    Evaluation of Prostate Cancer with 11C- and 18F-Choline PET/CT: Diagnosis and Initial Staging.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  24. SPICK C, Herrmann K, Czernin J
    Evaluation of Prostate Cancer with 11C-Acetate PET/CT.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  25. JADVAR H
    PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  26. JADVAR H
    Radiotheranostics in Prostate Cancer: Introduction and Overview.
    J Nucl Med. 2016;57.
    PubMed     Text format    


  27. IAGARU AH, Mittra E, Colletti PM, Jadvar H, et al
    Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  28. CHEN FK, de Castro Abreu AL, Palmer SL
    Utility of Ultrasound in the Diagnosis, Treatment, and Follow-up of Prostate Cancer: State of the Art.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  29. LINDENBERG L, Ahlman M, Turkbey B, Mena E, et al
    Evaluation of Prostate Cancer with PET/MRI.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  30. KILCOYNE A, Harisinghani MG, Mahmood U
    Prostate Cancer Imaging and Therapy: Potential Role of Nanoparticles.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


    September 2016
  31. AHMADZADEHFAR H, Azgomi K, Hauser S, Wei X, et al
    68Ga-PSMA-11 PET as a gate-keeper for the treatment of metastatic prostate cancer with radium-223: proof of concept.
    J Nucl Med. 2016 Sep 22. pii: jnumed.116.178533.
    PubMed     Text format     Abstract available


  32. OKAMOTO S, Thieme A, Allmann J, D'Alessandria C, et al
    Radiation dosimetry for 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: Absorbed dose in normal organs and tumor lesions.
    J Nucl Med. 2016 Sep 22. pii: jnumed.116.178483.
    PubMed     Text format     Abstract available


  33. ROBU S, Schottelius M, Eiber M, Maurer T, et al
    Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer.
    J Nucl Med. 2016 Sep 15. pii: jnumed.116.178939.
    PubMed     Text format     Abstract available


  34. FERDINANDUS J, Eppard E, Gartner F, Kurpig S, et al
    Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617.
    J Nucl Med. 2016 Sep 1. pii: jnumed.116.178228.
    PubMed     Text format     Abstract available


    August 2016
  35. OYEN WJ, de Bono JS
    Targeted alpha-based treatment of metastatic castration-resistant prostate cancer patients: revolutionizing systemic radiotherapy?
    J Nucl Med. 2016 Aug 18. pii: jnumed.116.179887.
    PubMed     Text format    


  36. DE BOER P, Piet AH, Oprea-Lager DE, Slotman B, et al
    Letter: PET-guided stereotactic irradiation of prostate cancer lymph node metastases.
    J Nucl Med. 2016 Aug 18. pii: jnumed.116.181149.
    PubMed     Text format    


  37. PANDIT-TASKAR N, O'Donoghue JA, Ruan S, Lyashchenko S, et al
    First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.
    J Nucl Med. 2016 Aug 11. pii: jnumed.116.176206.
    PubMed     Text format     Abstract available


  38. ZHANG H, Desai P, Koike Y, Houghton J, et al
    Dual modality imaging of prostate cancer with a fluorescent and radiogallium-labeled GRP receptor antagonist.
    J Nucl Med. 2016 Aug 11. pii: jnumed.116.176099.
    PubMed     Text format     Abstract available


  39. NOCK BA, Kaloudi A, Lymperis E, Giarika A, et al
    Theranostic perspectives in prostate cancer with the GRPR-antagonist NeoBOMB1 - Preclinical and first clinical results.
    J Nucl Med. 2016 Aug 4. pii: jnumed.116.178889.
    PubMed     Text format     Abstract available


    July 2016
  40. HARADA N, Kimura H, Onoe S, Watanabe H, et al
    Synthesis and Biological Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for Positron Emission Tomography of Prostate Cancer.
    J Nucl Med. 2016 Jul 14. pii: jnumed.116.175810.
    PubMed     Text format     Abstract available


  41. KRATOCHWIL C, Bruchertseifer F, Giesel FL, Weis M, et al
    225Ac-PSMA-617 for PSMA targeting alpha-radiation therapy of patients with metastatic castration-resistant prostate cancer.
    J Nucl Med. 2016 Jul 7. pii: jnumed.116.178673.
    PubMed     Text format     Abstract available


    June 2016
  42. RAUSCHER I, Maurer T, Beer AJ, Graner FP, et al
    Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy.
    J Nucl Med. 2016 Jun 3. pii: jnumed.116.173492.
    PubMed     Text format     Abstract available


  43. FENDLER WP, Schmidt DF, Wenter V, Thierfelder KM, et al
    68Ga-PSMA-HBED-CC PET/CT detects location and extent of primary prostate cancer.
    J Nucl Med. 2016 Jun 3. pii: jnumed.116.172627.
    PubMed     Text format     Abstract available


    April 2016
  44. RAHBAR K, Schmidt M, Heinzel A, Eppard E, et al
    Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis.
    J Nucl Med. 2016 Apr 7. pii: jnumed.116.173757.
    PubMed     Text format     Abstract available


    March 2016
  45. KRATOCHWIL C, Giesel FL, Stefanova M, Benesova M, et al
    PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617.
    J Nucl Med. 2016 Mar 16. pii: jnumed.115.171397.
    PubMed     Text format     Abstract available


    February 2016
  46. KWEKKEBOOM DJ
    Perspective on 177Lu-PSMA therapy of metastatic castration-resistant prostate cancer.
    J Nucl Med. 2016 Feb 18. pii: jnumed.115.171363.
    PubMed     Text format    


  47. LEE JH, Sato M, Coel MN, Lee KH, et al
    Prediction of PSA Progression in Castrate-Resistant Prostate Cancer based on Treatment-Associated Change in Tumor Burden Quantified by 18F-fluorocholine PET/CT.
    J Nucl Med. 2016 Feb 16. pii: jnumed.115.169177.
    PubMed     Text format     Abstract available


    January 2016
  48. APOLO AB, Lindenberg L, Shih JH, Mena E, et al
    Prospective Study Evaluating Na18F-Positron Emission Tomography/Computed Tomography (NaF-PET/CT) in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer.
    J Nucl Med. 2016 Jan 21. pii: jnumed.115.166512.
    PubMed     Text format     Abstract available


  49. BAUM RP, Kulkarni HR, Schuchardt C, Singh A, et al
    Lutetium-177 PSMA Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
    J Nucl Med. 2016 Jan 21. pii: jnumed.115.168443.
    PubMed     Text format     Abstract available


  50. RAHBAR K, Weckesser M, Huss S, Semjonow A, et al
    Correlation of intraprostatic tumor extent with 68-Ga-PSMA distribution in patients with prostate cancer.
    J Nucl Med. 2016 Jan 14. pii: jnumed.115.169243.
    PubMed     Text format     Abstract available


  51. LARSON SM
    EXINI Quantitative Bone Scan Index: Expanded Utility for the Planar Radionuclide Bone Scan.
    J Nucl Med. 2016;57:5-6.
    PubMed     Text format    


    December 2015
  52. OPREA-LAGER DE, Kramer G, van de Ven P, van den Eertwegh A, et al
    Repeatability of quantitative 18F-fluoromethylcholine PET/CT studies in prostate cancer.
    J Nucl Med. 2015 Dec 23. pii: jnumed.115.167692.
    PubMed     Text format     Abstract available


  53. MINAMIMOTO R, Hancock S, Schneider B, Chin F, et al
    Pilot Comparison of 68Ga-RM2 PET and 68Ga-PSMA PET in Patients with Biochemically Recurrent Prostate Cancer.
    J Nucl Med. 2015 Dec 10. pii: jnumed.115.168393.
    PubMed     Text format     Abstract available


    November 2015
  54. PYKA T, Weirich G, Einspieler I, Maurer T, et al
    [68Ga]PSMA-HBED PET for differential diagnosis of suspicious lung lesions in patients with prostate cancer.
    J Nucl Med. 2015 Nov 19. pii: jnumed.115.164442.
    PubMed     Text format     Abstract available


  55. VERWER EE, Lammertsma AA, Boellaard R
    Reply: Simplified Methods for Quantification of 18F-Fluoromethylcholine Uptake: Is SUVAUC,PP Actually an SUV?
    J Nucl Med. 2015;56:1806-7.
    PubMed     Text format    


  56. LAFFON E, de Clermont H, Marthan R
    Simplified Methods for Quantification of 18F-Fluoromethylcholine Uptake: Is SUVAUC,PP Actually an SUV?
    J Nucl Med. 2015;56:1806.
    PubMed     Text format    


    October 2015
  57. ROWE SP, Macura KJ, Ciarallo A, Mena E, et al
    Comparison of PSMA-based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer.
    J Nucl Med. 2015 Oct 22. pii: jnumed.115.163782.
    PubMed     Text format     Abstract available


    September 2015
  58. INCERTI E, Fodor A, Mapelli P, Fiorino C, et al
    Radiation treatment of lymph node recurrence from prostate cancer: is 11C-choline PET/CT predictive of survival outcomes?
    J Nucl Med. 2015 Sep 24. pii: jnumed.115.163741.
    PubMed     Text format     Abstract available


  59. MINAMIMOTO R, Loening A, Jamali M, Barkhodari A, et al
    Prospective Comparison of 99mTc MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT and Whole-Body MRI in Patients with Breast and Prostate Cancers.
    J Nucl Med. 2015 Sep 24. pii: jnumed.115.162610.
    PubMed     Text format     Abstract available


    August 2015
  60. ANAND A, Morris MJ, Kaboteh R, Bath L, et al
    Analytical Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize the Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer.
    J Nucl Med. 2015 Aug 27. pii: jnumed.115.160085.
    PubMed     Text format     Abstract available


  61. AFSHAR-OROMIEH A, Hetzheim H, Kratochwil C, Benesova M, et al
    The novel theranostic PSMA-ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry and first evaluation of tumor lesions.
    J Nucl Med. 2015 Aug 20. pii: jnumed.115.161299.
    PubMed     Text format     Abstract available



  62. SNMMI 2015 Image of the Year.
    J Nucl Med. 2015;56:9N.
    PubMed     Text format    


  63. HU K, Wang H, Tang G, Huang T, et al
    In Vivo Cancer Dual-Targeting and Dual-Modality Imaging with Functionalized Quantum Dots.
    J Nucl Med. 2015;56:1278-84.
    PubMed     Text format     Abstract available


  64. WEINEISEN M, Schottelius M, Simecek J, Baum RP, et al
    68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
    J Nucl Med. 2015;56:1169-76.
    PubMed     Text format     Abstract available


    July 2015
  65. CHITTENDEN SJ, Hindorf C, Parker CC, Lewington VJ, et al
    A Phase 1, open-label study of the biodistribution, pharmacokinetics and dosimetry of Radium-223 dichloride (223Ra dichloride) in patients with hormone refractory prostate cancer and skeletal metastases.
    J Nucl Med. 2015 Jul 16. pii: jnumed.115.157123.
    PubMed     Text format     Abstract available


  66. KIESS A, Minn I, Chen Y, Hobbs RF, et al
    Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen.
    J Nucl Med. 2015 Jul 16. pii: jnumed.115.155929.
    PubMed     Text format     Abstract available


  67. FAHEY F, Zukotynski K, Jadvar H, Capala J, et al
    Proceedings of the Second NCI-SNMMI Workshop on Targeted Radionuclide Therapy.
    J Nucl Med. 2015;56:1119-29.
    PubMed     Text format    


    June 2015
  68. MORIGI JJ, Stricker P, Van Leeuwen P, Tang R, et al
    Prospective Comparison of the detection rate of18F-Fluoromethylcholine and 68Ga-PSMA-HBED PET/CT in men with prostate cancer with rising PSA post curative treatment, being considered for targeted therapy.
    J Nucl Med. 2015 Jun 25. pii: jnumed.115.160382.
    PubMed     Text format     Abstract available


  69. ROWE SP, Gage KL, Faraj SF, Macura K, et al
    18F-DCFBC PET/CT for PSMA-based Detection and Characterization of Primary Prostate Cancer.
    J Nucl Med. 2015 Jun 11. pii: jnumed.115.154336.
    PubMed     Text format     Abstract available


  70. ETCHEBEHERE E, Araujo JC, Fox PS, Swanston NM, et al
    Prognostic factors in patients treated with radium-223: the role of skeletal tumor burden on baseline 18F-fluoride-PET/CT in predicting overall survival.
    J Nucl Med. 2015 Jun 11. pii: jnumed.115.158626.
    PubMed     Text format     Abstract available


  71. HERRMANN K, Bluemel C, Weineisen M, Schottelius M, et al
    Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy.
    J Nucl Med. 2015;56:855-61.
    PubMed     Text format     Abstract available


    May 2015
  72. JADVAR H
    PSMA PET in Prostate Cancer.
    J Nucl Med. 2015 May 14. pii: jnumed.115.157339.
    PubMed     Text format    


  73. CHATALIC KL, Veldhoven-Zweistra J, Bolkestein M, Hoeben S, et al
    A novel 111In-labeled anti-PSMA nanobody for targeted SPECT/CT imaging of prostate cancer.
    J Nucl Med. 2015 May 14. pii: jnumed.115.156729.
    PubMed     Text format     Abstract available


  74. LOHRMANN C, Zhang H, Thorek DL, Desai P, et al
    Cerenkov Luminescence Imaging for Radiation Dose Calculation of a (9)(0)Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
    J Nucl Med. 2015;56:805-11.
    PubMed     Text format     Abstract available


    March 2015
  75. EIBER M, Maurer T, Souvatzoglou M, Beer AJ, et al
    Evaluation of hybrid 68Ga-PSMA-ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy.
    J Nucl Med. 2015 Mar 19. pii: jnumed.115.154153.
    PubMed     Text format     Abstract available


  76. TIMMERMAND OV, Tran TA, Strand SE, Axelsson J, et al
    Intratherapeutic biokinetic measurements, dosimetry parameter estimates, and monitoring of treatment efficacy using cerenkov luminescence imaging in preclinical radionuclide therapy.
    J Nucl Med. 2015;56:444-9.
    PubMed     Text format     Abstract available


    April 2014
  77. LEWIS DY, Boren J, Shaw GL, Bielik R, et al
    Late Imaging with [1-11C]Acetate Improves Detection of Tumor Fatty Acid Synthesis with PET.
    J Nucl Med. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: